Federal research rule changes could reshape applied microbiology in America

For those unfamiliar with the Uniform Guidance, it is the rulebook governing how federal agencies distribute roughly $200 billion annually in research funding. The proposed revisions are far-reaching, but several provisions should concern the applied microbiology community directly.

What’s at stake

Under the proposed rule, evaluating grant proposals based on scientific merit could be deprioritized in favor of undefined “administration policies and priorities.” Hence, instead of a committee of our peers evaluating whether the work we propose to do is appropriate and rigorous, the government administration could make a unilateral decision as to the ‘value’ of the proposal to their agenda. This is important because while our research always contains societal bias (read Thomas Kuhn for a summary), a scientific merit-based system has allowed researchers to pursue research hypotheses developed based on the evidence, without interference from politics. If the government doesn’t agree that vaccine research is important, they would be able to reject your proposal irrespective of its potential scientific rigor and societal impact.

The proposed rule also grants agencies broad authority to terminate awards mid-project based on “national interest”, which is undefined and subject to political discretion. For an industry that depends on multi-year research collaborations, this creates unacceptable uncertainty. A company partnering with a university on a three-year product development project cannot absorb the risk of federal funding evaporating mid-stream. Hence, this would stifle public-private partnerships.

Additionally, the rule would severely restrict international research collaborations, thereby impacting global research initiatives. As problems like pathogen surveillance and biopharmaceutical manufacturing do not recognize borders, this action is very short-sighted. Also, these restrictions would handicap American researchers and push expertise abroad, even more so than has already been happening.

Why this matters for industry as well as universities

Many industrial biotech companies, food safety firms, and environmental consultancies leverage federally funded research both within their enterprise and through direct collaboration with universities, which are still the powerhouse of US intellectual property development. Constraints on what science can be done, uncertainty around grant survival, and restrictions on international collaboration would compromise access to critical expertise, make long-term development projects unviable, and eliminate research that is aligned with the current government’s agenda. This is the exact kind of overreach that stifles innovation and creativity.

What you can do

You have until July 13, 2026, 11:59 pm EST to submit a comment to regulations.gov. The submission process takes about five minutes.

Here’s how to make your voice count:

Submit a personal comment with specific examples of how these changes would affect your work. “This threatens pandemic preparedness” is weak and won’t help. “Our industrial consortium’s five-year mycotoxin reduction project would be vulnerable to termination” is powerful. Specific, concrete impacts carry weight in administrative proceedings.

If you are in the US, please contact your Senators and Representatives. Share your regulatory comment with them.

The research community’s response will establish an administrative record that informs any future legal or legislative effort to overturn these rules. The number and quality of comments matter, because they demonstrate concern and provide an evidential record of the far-reaching implications of such action.

Applied microbiology has thrived because scientists could follow evidence and industry could partner with universities on multi-year research. These proposed rules threaten both. Your voice in this comment period is essential.